Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes

In the paper

“Although all but one of these patients required supplemental insulin 10 years post-transplant, all recipients retained some level of graft function that provided substantial benefits to glucose control and elimination of severe hypoglycemic events.17”

What the sources say

• Disputed

  Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Checked by a reasoning model — may be wrong.

  cites [17] Brennan DC, Kopetskie HA, and Sayre PH (2016). Long-term follow-up of the Edmonton Protocol of islet transplantation in the United States. Am. J. Transplant 16, 509– 517. 26433206 sourceExperimental — accuracy not yet measured

In the paper

“Transplantation of pancreatic islets alone to restore β cell mass, however, had limited success until the development of the Edmonton Protocol in 2000, which demonstrated that infusion of islets into the liver via the portal vein was sufficient to restore glucose homeostasis.15,16”

What the sources say

• ?Not checked — no full text of the sourcecites [15] Shapiro J, Lakey JRT, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, and Rajotte RV (2000). Islet transplantation in seven patients with T1D using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med 343, 230– 238. 10911004 source
• Partly supported

  “A new millennium begins” reports that the 2000 Edmonton Protocol achieved insulin independence in seven patients, a substantial improvement over earlier results. But “Islet transplantation in the twentieth century” reports insulin independence after intraportal transplantation before 2000, so the source does not support the implication that Edmonton first demonstrated that portal-vein islet infusion could restore glucose control. No page numbers are provided in our copy. (LLM, conf=0.88)

  cites [16] Bottino R, Knoll MF, Knoll CA, Bertera S, and Trucco MM (2018). The future of islet transplantation is now. Front. Med 5, 1– 13. PMC6053495 30057900 sourceExperimental — accuracy not yet measured

In the paper

“Interestingly, while there were regions of C-peptide positive β-like cells, a majority of these endocrine cells stained for the α cell marker glucagon. Ductal cells and rare acinar cells were also observed.”

What the sources say

• Partly supported

  The Results (page not provided) describe insulin-immunoreactive cells with a mature β-cell phenotype, an explanted endocrine population enriched in glucagon-positive cells, and scattered duct-like structures. They report few acinar cells in devices that were never implanted, but do not establish that acinar cells were rare in the explanted grafts or describe C-peptide-positive staining of β-like cells. (LLM, conf=0.82)

  cites [33] Ramzy A, Thompson DM, Ward-Hartstonge KA, Ivison S, Cook L, Garcia RV, Loyal J, Kim PTW, Warnock GL, Levings MK, (2021). Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell 28, 2047– 2061. 34861146 sourceExperimental — accuracy not yet measured
• Partly supported

  In Results > Histology of explanted units (page unavailable), the paper describes insulin-expressing β-like cells and reports that glucagon staining was more abundant than insulin staining. It does not establish that a majority of endocrine cells stained for glucagon, or identify the stained cells as C-peptide-positive. In Discussion > Limitations of the study (page unavailable), it reports minority ductal and very rare exocrine cells from an accompanying study, while stating that it lacks its own counts of ductal and acinar cells. (LLM, conf=0.84)

  cites [35] Shapiro AMJ, Thompson D, Donner TW, Bellin MD, Hsueh W, Pettus J, Wilensky J, Daniels M, Wang RM, Brandon EP, (2021). Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Reports Med. 2, 100466. PMC8714853 35028608 sourceExperimental — accuracy not yet measured

In the paper

“Subsequent transplantation studies continued to show improved patient outcomes, with islet transplantation approaching the success of whole pancreas transplantation without the corresponding surgical risk.18–23”

What the sources say

• Supported

  The Abstract Results report improved outcomes across transplant eras, including three-year insulin independence rising from 27% to 44%. The Conclusions compare recent islet graft survival favorably with whole-pancreas graft survival, while noting that insulin independence remained lower (44% versus 61%). They also describe islet transplantation as a minimally invasive alternative for patients unwilling or unable to accept the risks of major surgery. (LLM, conf=0.92)

  cites [18] Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, Oberholzer J, Odorico JS, Garfinkel MR, Levy M, (2012). Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 35, 1436– 1445. 22723582 PMC3379615 source
• ?Not checked — no full text of the sourcecites [19] Vantyghem MC, Chetboun M, Gmyr V, Jannin A, Espiard S, Le Mapihan K, Raverdy V, Delalleau N, MacHuron F, Hubert T, (2019). Ten-year outcome of islet alone or islet after kidney transplantation in type 1 diabetes: A prospective parallel-arm cohort study. Diabetes Care 42, 2042– 2049. 31615852 source
• Partly supported

  The Methods findings (page unavailable) report insulin independence and sustained improvements in glycaemic control after islet transplantation. They do not establish that its success approaches whole-pancreas transplantation or that it avoids the corresponding surgical risk; the study did not compare those procedures. (LLM, conf=0.86)

  cites [20] Marfil-Garza BA, Imes S, Verhoeff K, Hefler J, Lam A, Dajani K, Anderson B, O’Gorman D, Kin T, Bigam D, (2022). Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada. Lancet Diabetes Endocrinol. 10, 519– 532. 35588757 sourceExperimental — accuracy not yet measured
• Supported

  The Discussion (page not provided) reports similar three-year graft survival for islet and pancreas transplantation in selected patients with type 1 diabetes, while islet recipients had shorter hospitalizations and fewer serious complications. It also reports higher and longer-lasting insulin independence than in earlier islet-transplant data. These findings support the cited comparison, within the study’s selected population. (LLM, conf=0.88)

  cites [21] Moassesfar S, Masharani U, Frassetto LA, Szot GL, Tavakol M, Stock PG, and Posselt AM (2016). A comparative analysis of the safety, efficacy, and cost of islet versus pancreas transplantation in nonuremic patients with type 1 diabetes. Am. J. Transplant 16, 518– 526. 26595767 PMC5549848 source
• ?Not checked — no full text of the sourcecites [22] Shapiro AMJ, and Verhoeff K (2022). A spectacular year for islet and stem cell transplantation. Nat. Rev. Endocrinol 10. 36539606 source
• ?Not checked — no full text of the sourcecites [23] Verhoeff K, Marfil-Garza BA, and Shapiro AMJ (2021). Update on islet cell transplantation. Curr. Opin. Organ Transplant 26, 397– 404. 34148980 source

In the paper

“As intended, the porous design promoted the growth of host-derived blood vessels inside the device, and this phenomenon was more prominent in regions containing the graft-derived cells.”

What the sources say

• Partly supported

  The Introduction describes portals designed to let capillaries enter the device, and the Results report blood vessels in explanted devices and endothelial staining adjacent to insulin-positive graft cells. The paper does not report that vascular growth was more prominent in regions containing graft-derived cells than elsewhere in the device. (LLM, conf=0.84)

  cites [33] Ramzy A, Thompson DM, Ward-Hartstonge KA, Ivison S, Cook L, Garcia RV, Loyal J, Kim PTW, Warnock GL, Levings MK, (2021). Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell 28, 2047– 2061. 34861146 sourceExperimental — accuracy not yet measured
• Supported

  The Results section, “Histology of explanted units,” reports blood vessels within the device lumen that traversed membrane ports. It also reports a robust vessel network in regions containing graft cells and 10-fold higher vessel density there than in non-cellular regions. The STAR Methods section says the membrane portals were designed to allow the subject’s vasculature to grow into the graft. (LLM, conf=0.94)

  cites [35] Shapiro AMJ, Thompson D, Donner TW, Bellin MD, Hsueh W, Pettus J, Wilensky J, Daniels M, Wang RM, Brandon EP, (2021). Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Reports Med. 2, 100466. PMC8714853 35028608 source

In the paper

“While some endocrine cells were observed, fibrosis around the capsule resulted in graft loss, and no insulin secretion from the device was detected.33,34”

What the sources say

• Supported

  The Introduction (page not available) reports that some explanted grafts from the earlier encapsulation-device trial contained insulin-immunoreactive cells, but a foreign-body response made cell survival inconsistent and there was no reported evidence of insulin secretion. It also describes cell loss due to device fibrosis. This is a report of the earlier device, not the outcome of this paper’s follow-up trial, which detected meal-responsive C-peptide. (LLM, conf=0.89)

  cites [33] Ramzy A, Thompson DM, Ward-Hartstonge KA, Ivison S, Cook L, Garcia RV, Loyal J, Kim PTW, Warnock GL, Levings MK, (2021). Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell 28, 2047– 2061. 34861146 source
• Partly supported

  In “Bounding into the Clinic” (page not specified), the paper says pancreatic precursors in ViaCyte’s device grew into insulin-producing β-cells in many recipients, but often died after a few months because of a fibrotic reaction on the device exterior. It does not say that no insulin secretion from the device was detected. (LLM, conf=0.86)

  cites [34] Dolgin E. (2016). Encapsulating the problem. Nature 540, S60– 62. 27926697 sourceExperimental — accuracy not yet measured

In the paper

“In particular, graft success increases when a high number of islets are transplanted, often resulting in the need for multiple donor pancreases. 15,20,24”

What the sources say

• ?Not checked — no full text of the sourcecites [15] Shapiro J, Lakey JRT, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, and Rajotte RV (2000). Islet transplantation in seven patients with T1D using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med 343, 230– 238. 10911004 source
• ?Could not verify

  The Methods and Findings passages report graft survival and factors associated with sustained survival, but do not link success to the number of islets transplanted. Searches for islet mass, islet equivalents, and multiple donor pancreases found no passage establishing that relationship or the claimed need for multiple donors; a relevant study appears only in the References. (LLM, conf=0.72)

  cites [20] Marfil-Garza BA, Imes S, Verhoeff K, Hefler J, Lam A, Dajani K, Anderson B, O’Gorman D, Kin T, Bigam D, (2022). Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada. Lancet Diabetes Endocrinol. 10, 519– 532. 35588757 sourceExperimental — accuracy not yet measured
• Partly supported

  The Results (‘The common favourable factors’; page unavailable) associate at least 325,000 infused islet equivalents with more favourable outcomes in the studied recipients. The Introduction says 74% received at least two islet infusions, but does not establish that achieving a high islet dose often requires multiple donor pancreases; the observational association also does not establish causation. (LLM, conf=0.86)

  cites [24] Hering BJ, Ballou CM, Bellin MD, Payne EH, Kandeel F, Witkowski P, Alejandro R, Rickels MR, and Barton FB (2022). Factors associated with favourable 5 year outcomes in islet transplant alone recipients with type 1 diabetes complicated by severe hypoglycaemia in the Collaborative Islet Transplant Registry. Diabetologia, 163– 173. 36201044 PMC10355148 sourceExperimental — accuracy not yet measured

In the paper

“While the transplanted PEC-Encap product was well tolerated with few adverse effects, the trial was halted due to insufficient functional product engraftment.33”

What the sources say

• Partly supported

  The Introduction (page unavailable) says the first 19 PEC-Encap recipients tolerated the product well with few complications. It also reports inconsistent cell survival and no evidence of insulin secretion, but does not say the trial was halted or give insufficient functional engraftment as the reason for halting it. (LLM, conf=0.86)

  cites [33] Ramzy A, Thompson DM, Ward-Hartstonge KA, Ivison S, Cook L, Garcia RV, Loyal J, Kim PTW, Warnock GL, Levings MK, (2021). Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell 28, 2047– 2061. 34861146 sourceExperimental — accuracy not yet measured

In the paper

“An ongoing clinical trial was started in 2017 at seven sites to test this device (clinicaltrials.gov: NCT03163511), and the first round of results have recently been published.33,35”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [33] Ramzy A, Thompson DM, Ward-Hartstonge KA, Ivison S, Cook L, Garcia RV, Loyal J, Kim PTW, Warnock GL, Levings MK, (2021). Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell 28, 2047– 2061. 34861146 source
• Partly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [35] Shapiro AMJ, Thompson D, Donner TW, Bellin MD, Hsueh W, Pettus J, Wilensky J, Daniels M, Wang RM, Brandon EP, (2021). Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Reports Med. 2, 100466. PMC8714853 35028608 sourceExperimental — accuracy not yet measured

In the paper

“Interestingly, SC-EC cells also persisted after transplantation and exhibited increased expression of key gene markers of their identity, such as TPH1.”

What the sources say

• Partly supported

  The Results section, “Transcriptional Changes of EC Cells within Transplanted Grafts” (page unavailable), says SC-EC cells continue to exist after transplantation and lists several EC-cell genes that are upregulated. It says TPH1 protein is expressed after transplantation, but does not say TPH1 gene expression increased. (LLM, conf=0.86)

  cites [51] Augsornworawat P, Maxwell KG, Velazco-Cruz L, and Millman JR (2020). Single-cell transcriptome profiling reveals β cell maturation in stem cell-derived islets after transplantation. Cell Rep. 32, 108067. 32846125 PMC7491368 sourceExperimental — accuracy not yet measured
• Not checked yetcites [75] Augswornworawat P, Hogrebe NJ, Ishahak M, Marquez E, Maestas M, Schmidt M, Veronese-Paniagua D, Gale S, Miller J, Velazco-Cruz L, (2022). Defining the chromatin and transcriptional landscape of stem cell-derived islets. BioRxiv, 1– 59.

In the paper

“These transcriptional changes appeared to occur temporally, as some genes (e.g., G6PC2) increased in expression shortly after transplantation, while others (e.g., MAFA) took several months to upregulate.”

What the sources say

• Partly supported

  The Results section reports that MAFA was sharply upregulated at six months postengraftment, supporting the claim that it took months. It says G6PC2 increased early in in vitro culture, not shortly after transplantation, although it also reports further upregulation following engraftment without specifying when that occurred. (LLM, conf=0.88)

  cites [43] Balboa D, Barsby T, Lithovius V, Saarimäki-Vire J, Omar-Hmeadi M, Dyachok O, Montaser H, Lund PE, Yang M, Ibrahim H, (2022). Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells. Nat. Biotechnol 40, 1042– 1055. 35241836 PMC9287162 sourceExperimental — accuracy not yet measured
• Partly supported

  The Results section (‘SC-β Cells Mature within Transplanted Grafts’; page unavailable) reports that both G6PC2 and MAFA increase after transplantation and with pseudotime. The Discussion says some maturation genes are expressed before MAFA in pseudotime, but does not identify G6PC2 as one of them. Pseudotime does not establish that G6PC2 rose shortly after transplantation or that MAFA took several months to rise. (LLM, conf=0.87)

  cites [51] Augsornworawat P, Maxwell KG, Velazco-Cruz L, and Millman JR (2020). Single-cell transcriptome profiling reveals β cell maturation in stem cell-derived islets after transplantation. Cell Rep. 32, 108067. 32846125 PMC7491368 sourceExperimental — accuracy not yet measured

In the paper

“Transplantation of SC-islets into mice improves their insulin secretion and glucose responsiveness, suggesting that SC-islet immaturity can be resolved.”

What the sources say

• Partly supported

  The Results section, “Stem Cell-Derived β Cells Function in vivo After Transplantation” (page unavailable), reports human insulin secretion and a response to glucose within two weeks of transplantation. It does not show that transplantation improved either property relative to the cells before transplantation. The separate Results section on in vitro function reports that SC-β cells were already glucose-responsive, so the proposed resolution of their immaturity is not established here. (LLM, conf=0.87)

  cites [36] Pagliuca FW, Millman JR, Gu M, Segel M, Dervort A. Van, Ryu JH, Peterson QP, Greiner D, and Melton DA (2014). Generation of functional human pancreatic ß-Cells in vitro. Cell 159, 428– 439. 25303535 PMC4617632 sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [37] Rezania A, Bruin JE, Arora P, Rubin A, Batushansky I, Asadi A, O’Dwyer S, Quiskamp N, Mojibian M, Albrecht T, (2014). Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol 32, 1121– 1133. 25211370 source
• Partly supported

  The Abstract reports human C-peptide secretion and glucose responsiveness after SC-β-cell transplantation into diabetic mice. But it describes the cells as mature and glucose-responsive before transplantation, and says they maintained their differentiation state afterward. It does not show that transplantation improved their function or resolved immaturity. (LLM, conf=0.88)

  cites [41] Vegas AJ, Veiseh O, Gürtler M, Millman JR, Pagliuca FW, Bader AR, Doloff JC, Li J, Chen M, Olejnik K, (2016). Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat. Med 22, 306– 311. 26808346 PMC4825868 sourceExperimental — accuracy not yet measured
• Partly supported

  The Results section, “Transplantation of SC-β Cells into Glucose-Intolerant Mice” (page unavailable), reports glucose-responsive human insulin secretion after transplantation and improved glucose tolerance in recipient mice. But it does not show that transplantation improved the cells’ insulin secretion or glucose responsiveness relative to before transplantation. The Discussion instead attributes enhanced functional maturation to the six-stage differentiation strategy, so the claim that transplantation resolves immaturity is not supported. (LLM, conf=0.86)

  cites [42] Velazco-Cruz L, Song J, Maxwell KG, Goedegebuure MM, Augsornworawat P, Hogrebe NJ, and Millman JR (2019). Acquisition of dynamic function in human stem cell-derived β cells. Stem Cell Reports 12, 351– 365. 30661993 PMC6372986 sourceExperimental — accuracy not yet measured
• Partly supported

  The Results section, “SC-islets control the glycemia of mice in vivo” (page unavailable), reports glucose-regulated insulin secretion after engraftment, with higher C-peptide levels and faster glucose clearance for grafts matured longer in vitro. The Discussion (page unavailable) reports continued maturation after engraftment, but does not establish that transplantation itself improved insulin secretion or fully resolved SC-islet immaturity. (LLM, conf=0.84)

  cites [43] Balboa D, Barsby T, Lithovius V, Saarimäki-Vire J, Omar-Hmeadi M, Dyachok O, Montaser H, Lund PE, Yang M, Ibrahim H, (2022). Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells. Nat. Biotechnol 40, 1042– 1055. 35241836 PMC9287162 sourceExperimental — accuracy not yet measured
• Partly supported

  The Results section, “Rapid onset of eBC functionality in vivo within days of transplantation” (page unavailable), reports glucose-responsive C-peptide secretion three days after transplantation and higher secretion eight months later. But the paper attributes the acquisition of mature glucose responsiveness chiefly to clustering in culture: the transplanted eBCs were already functional. It therefore does not establish that transplantation itself resolves SC-islet immaturity. (LLM, conf=0.85)

  cites [44] Nair GG, Liu JS, Russ HA, Tran S, Saxton MS, Chen R, Juang C, Li M. Ian, Nguyen VQ, Giacometti S, (2019). Recapitulating endocrine cell clustering in culture promotes maturation of human stem-cell-derived β cells. Nat. Cell Biol 21, 263– 274. 30710150 PMC6746427 sourceExperimental — accuracy not yet measured

In the paper

“Previous analysis of scRNA-seq data alone had suggested that SC-β and SC-EC are distinct cell types that share a common progenitor lineage during in vitro differentiation of SC-islets,”

What the sources say

• Supported

  In “The origin and lineage of SC-β cells” (page not supplied), the paper says its single-cell sequencing analysis suggests that SC-β and SC-EC cells emerge from a common NEUROG3+ intermediate through a late fate bifurcation. The Discussion (page not supplied) describes them as closely related but fundamentally distinct. (LLM, conf=0.92)

  cites [47] Veres A, Faust AL, Bushnell HL, Engquist EN, Kenty JH, Harb G, Quinn P, Poh Y, Sintov E, Gürtler M, Charting cellular identity during human in vitro β - cell differentiation. Nature, 368– 373. PMC6903417 31068696 source
• Supported

  The Results section, “A time-series single cell transcriptomic atlas,” identifies distinct β-like and EC-like populations in the final differentiation stage. In “Reconstruct a lineage tree,” the authors report that the endocrine cells originated from the same modeled S5 trajectory, supporting the claim of a shared progenitor lineage. The analysis uses single-cell transcriptomic data. (LLM, conf=0.88)

  cites [50] Weng C, Xi J, Li H, Cui J, Gu A, Lai S, Leskov K, Ke L, Jin F, and Li Y (2020). Single-cell lineage analysis reveals extensive multimodal transcriptional control during directed beta-cell differentiation. Nat. Metab 2, 1443– 1458. 33257854 PMC7744443 source

In the paper

“One of the most interesting findings from these scRNA-seq studies was the identification of SC-EC cells, which are absent from primary human islets and resemble an endocrine cell type normally found in the intestines.”

What the sources say

• Partly supported

  The SC-islets and SC-EC cells sections identify SC-EC cells and describe their resemblance to gut enterochromaffin cells. The Discussion says enterochromaffin cells have not previously been observed in studies of human islets, but also notes rare evidence suggesting resident pancreatic enterochromaffin cells; it does not establish that they are categorically absent from primary human islets. Page numbers are unavailable in our copy. (LLM, conf=0.86)

  cites [47] Veres A, Faust AL, Bushnell HL, Engquist EN, Kenty JH, Harb G, Quinn P, Poh Y, Sintov E, Gürtler M, Charting cellular identity during human in vitro β - cell differentiation. Nature, 368– 373. PMC6903417 31068696 sourceExperimental — accuracy not yet measured

In the paper

“1,150 endocrine-specific switch genes were identified, and it was inferred that 656 pairs of transcription factor and target gene interactions potentially influenced endocrine specification.”

What the sources say

• Supported

  The Results section, “Switch genes mark cell fate choice and guide the improvement of differentiation protocol,” reports 1,150 endocrine-specific switch genes at BP1 and 656 potential TF–target gene pairs among the endocrine switch genes. It describes those pairs as possible regulatory relationships, consistent with the claim’s tentative wording. Page numbers were not provided in our copy. (LLM, conf=0.95)

  cites [50] Weng C, Xi J, Li H, Cui J, Gu A, Lai S, Leskov K, Ke L, Jin F, and Li Y (2020). Single-cell lineage analysis reveals extensive multimodal transcriptional control during directed beta-cell differentiation. Nat. Metab 2, 1443– 1458. 33257854 PMC7744443 source

In the paper

“Because SC-EC cells comprise a significant percentage of the final cell population in SC-islets but do not secrete insulin, differentiation efficiency and SC-islet insulin secretion on a per cell basis could be greatly improved by diverting these SC-EC cells toward a SC-β cell lineage during either the cell specification or maturation stages.”

What the sources say

• Partly supported

  The “SC-islets contain four major cell types” section identifies SC-EC cells as a population present at the final differentiation stages. The “SC-EC cells” section reports low levels of insulin and serotonin release, but does not establish that SC-EC cells secrete no insulin. Page numbers are unavailable in our copy. (LLM, conf=0.84)

  cites [47] Veres A, Faust AL, Bushnell HL, Engquist EN, Kenty JH, Harb G, Quinn P, Poh Y, Sintov E, Gürtler M, Charting cellular identity during human in vitro β - cell differentiation. Nature, 368– 373. PMC6903417 31068696 sourceExperimental — accuracy not yet measured

In the paper

“These cells are characterized by the expression of enterochromaffin gene markers, such as TPH1 and LMX1A, as well as the secretion of serotonin rather than insulin.”

What the sources say

• Partly supported

  The “SC-EC cells” section reports TPH1 and LMX1A expression, serotonin content, and serotonin release from SC-islets; Extended Data Fig. 5 describes SC-EC cells as secreting serotonin. But the paper also reports low levels of insulin in SC-EC cells and does not establish that these cells secrete serotonin instead of insulin. (LLM, conf=0.86)

  cites [47] Veres A, Faust AL, Bushnell HL, Engquist EN, Kenty JH, Harb G, Quinn P, Poh Y, Sintov E, Gürtler M, Charting cellular identity during human in vitro β - cell differentiation. Nature, 368– 373. PMC6903417 31068696 sourceExperimental — accuracy not yet measured

In the paper

“With less optimized protocols or cell lines, there is also the potential to retain progenitor cells in the final islet clusters as well as produce other endodermal cell types, such as those of hepatic origin.39,58”

What the sources say

• Partly supported

  The Introduction (page unavailable) says endodermal progenitors can produce non-pancreatic lineages, including hepatocytes. The Results section on cytoskeletal fate selection (page unavailable) also finds pancreatic progenitors and undefined endoderm under some differentiation conditions. These passages support the possibility of alternative cell fates, but they do not establish that less-optimized protocols or cell lines retain progenitors or produce hepatic cells in final islet clusters. (LLM, conf=0.84)

  cites [39] Hogrebe NJ, Augsornworawat P, Maxwell KG, Velazco-Cruz L, and Millman JR (2020). Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells. Nat. Biotechnol 38, 460– 470. 32094658 PMC7274216 sourceExperimental — accuracy not yet measured
• Partly supported

  The Introduction (page unavailable) says stem-cell-derived islets can retain progenitors and describes non-pancreatic endodermal tissues arising from contaminating cells, particularly gastrointestinal and respiratory epithelia. It does not identify cells of hepatic origin, so that example is not supported by this source. (LLM, conf=0.86)

  cites [58] Cuesta-Gomez N, Verhoeff K, Jasra IT, Pawlick R, Dadheech N, and Shapiro AMJ (2022). Characterization of stem-cell-derived islets during differentiation and after implantation. Cell Rep. 40, 111238. 36001981 sourceExperimental — accuracy not yet measured

In the paper

“Alternatively, the SC-islets themselves can be genetically engineered to both remove antigens that would signal them for destruction by the host immune system as well as add surface signaling molecules that induce immune tolerance.54,55”

What the sources say

• Partly supported

  The Results section, ‘Engineering immune-evasive SC-islet cells’ (page unavailable), describes SC-islets engineered to lack HLA class I antigens and express surface PD-L1. But those cells were rejected in the paper’s xenograft model; the localized tolerance reported in the Results and Discussion came from engineered secretion of cytokines, not from added surface signaling molecules. The claim therefore combines two approaches while overstating what the surface-molecule approach achieved. (LLM, conf=0.87)

  cites [54] Gerace D, Zhou Q, Kenty JH, Boulanger KR, Li H, Melton DA, Gerace D, Zhou Q, Kenty JH, Veres A, (2023). Engineering human stem cell-derived islets to evade immune rejection and promote localized immune tolerance. Cell Reports Med. 4, 100879. PMC9873825 36599351 sourceExperimental — accuracy not yet measured
• Supported

  The Introduction reports genetic deletion of HLAs from stem cells to reduce rejection. The Discussion proposes further modifying stem cell-derived islets through forced expression of the immune-checkpoint molecule PD-L1. The paper presents the combined approach as a possibility, consistent with the claim’s wording, rather than as an intervention it tested. (LLM, conf=0.88)

  cites [55] Parent AV, Faleo G, Chavez J, Saxton M, Berrios DI, Kerper NR, Tang Q, and Hebrok M (2021). Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection. Cell Rep. 36, 109538. 34407395 PMC12416289 source

In the paper

“This differentiation methodology takes approximately a month or more to complete, and functional maturation can continue for months once the cells are transplanted in vivo.43,51”

What the sources say

• Supported

  The Discussion describes a final six-week in vitro maturation step, so the differentiation methodology takes at least a month. It also reports continued maturation and dynamic in vivo function over six months of mouse engraftment. (LLM, conf=0.92)

  cites [43] Balboa D, Barsby T, Lithovius V, Saarimäki-Vire J, Omar-Hmeadi M, Dyachok O, Montaser H, Lund PE, Yang M, Ibrahim H, (2022). Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells. Nat. Biotechnol 40, 1042– 1055. 35241836 PMC9287162 source
• Partly supported

  The Results (Retrieval and Identification of SC-Islet Cell Populations after Transplantation; page unavailable) report improved glucose regulation after four weeks, further reversal of diabetes at six months, and increasing glucose-stimulated human C-peptide secretion. This supports functional maturation over months after transplantation. The Methods (Stem cell-derived β Cell differentiation; page unavailable) describe a six-stage protocol and transplantation on days 13–16 of stage 6, but do not establish that the full differentiation takes a month or more. (LLM, conf=0.86)

  cites [51] Augsornworawat P, Maxwell KG, Velazco-Cruz L, and Millman JR (2020). Single-cell transcriptome profiling reveals β cell maturation in stem cell-derived islets after transplantation. Cell Rep. 32, 108067. 32846125 PMC7491368 sourceExperimental — accuracy not yet measured

In the paper

“While these drugs can successfully retain graft viability, they also can have serious side-effects, including an increased risk of infection and cancer as well as less severe but uncomfortable symptoms.”

What the sources say

• ?Not checked — no full text of the sourcecites [79] Rickels MR, and Paul Robertson R (2019). Pancreatic islet transplantation in humans: Recent progress and future directions. Endocr. Rev 40, 631– 668. 30541144 PMC6424003 source
• Partly supported

  The Case Reports > Complications section describes immunosuppression-related mouth ulcers, a cellulitis episode requiring hospitalization and antibiotics, and declining renal function. The Discussion and Patient A report support preservation of islet graft function during immunosuppression, but the paper does not address increased cancer risk or establish an increased infection risk in whole-organ transplant recipients. Page numbers are unavailable in our copy. (LLM, conf=0.87)

  cites [80] Blau J, Abegg M, Flegel W, Zhao X, Harlan D, and Rother K (2015). Long-term immunosupression after solitary islet transplantation is associated with preserved C-peptide secretion for more than a decade. Am J Transpl. 15, 2995– 3001. PMC5158099 26184712 sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [81] Ryan E, Paty B, Senior P, and Shapiro J (2004). Risks and side effects of islet transplantation. Curr. Diab. Rep 4, 304– 309. 15265474 source

In the paper

“In particular, the amount of islet mass that is lost immediately following transplantation has been reduced closer to 25%, and thus fewer islets have been needed to achieve insulin independence.”

What the sources say

• ?Not checked — no full text of the sourcecites [79] Rickels MR, and Paul Robertson R (2019). Pancreatic islet transplantation in humans: Recent progress and future directions. Endocr. Rev 40, 631– 668. 30541144 PMC6424003 source
• Partly supported

  The Discussion reports improved functional islet mass with the CIT07 protocol and insulin independence achieved with fewer transplanted islets than under the historical Edmonton protocol. But the Abstract’s ∼25% figure refers to β-cell secretory capacity relative to normal in Edmonton-protocol recipients—not the percentage of islet mass lost immediately after transplantation. The paper does not quantify immediate loss under CIT07 as 25%. (LLM, conf=0.90)

  cites [125] Rickels MR, Liu C, Shlansky-Goldberg RD, Soleimanpour SA, Vivek K, Kamoun M, Min Z, Markmann E, Palangian M, Dalton-Bakes C, (2013). Improvement in β-Cell secretory capacity after human islet transplantation according to the CIT07 protocol. Diabetes 62, 2890– 2897. 23630300 PMC3717864 sourceExperimental — accuracy not yet measured

In the paper

“For example, a PTFE macroencapsulation device that actively pumped fluid through a hollow fiber running through its center demonstrated enhanced nutrient exchange that promoted cell survival and allowed for a greater cell density to be successfully loaded into the device.”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [94] Yang K, O’Cearbhaill ED, Liu SS, Zhou A, Chitnis GD, Hamilos AE, Xu J, Verma MKS, Giraldo JA, Kudo Y, (2021). A therapeutic convection-enhanced macroencapsulation device for enhancing β cell viability and insulin secretion. Proc. Natl. Acad. Sci 118, 1– 12. PMC8449352 34504013 source

In the paper

“These cells could be differentiated into endothelial cells or vascular smooth muscle cells and demonstrated improved survival in co-cultures with T-cells, NK cells, and macrophages.”

What the sources say

• Partly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [119] Han X, Wang M, Duan S, Franco PJ, Kenty JHR, Hedrick P, Xia Y, Allen A, Ferreira LMR, Strominger JL, (2019). Generation of hypoimmunogenic human pluripotent stem cells. Proc. Natl. Acad. Sci. U. S. A 116, 10441– 10446. 31040209 PMC6535035 sourceExperimental — accuracy not yet measured

In the paper

“While this pathway aims to restore protein homeostasis under mild stress conditions, it will induce apoptosis if the trigger is more severe.”

What the sources say

• Supported

  The “Life and death decisions” section states that mild ER stress can be mitigated to restore protein homeostasis and promote β-cell survival. It contrasts this with unresolvable ER stress, under which the UPR activates death effectors leading to β-cell apoptosis. The source describes the decisive distinction as resolvable versus unresolvable stress, rather than severity alone. (LLM, conf=0.92)

  cites [127] Fonseca SG, Gromada J, and Urano F (2011). Endoplasmic reticulum stress and pancreatic β-cell death. Trends Endocrinol. Metab 22, 266– 274. 21458293 PMC3130122 source

In the paper

“Interestingly, while decreasing the size of encapsulation devices down to the scale of individual islet microcapsules increases nutrient diffusion shortly after transplantation when compared to macroencapsulation devices, smaller capsule sizes have been shown to also induce a robust foreign body response and subsequent fibrosis.”

What the sources say

• Partly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [103] Veiseh O, Doloff JC, Ma M, Vegas AJ, Tam HH, Bader AR, Li J, Langan E, Wyckoff J, Loo WS, (2015). Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates. Nat. Mater 14, 643– 651. 25985456 PMC4477281 sourceExperimental — accuracy not yet measured

In the paper

“This design greatly enhanced islet survival upon transplantation into diabetic mice and allowed the device to be scaled up to 6.6 mm thick.”

What the sources say

• Supported

  The Discussion (page unavailable) describes the SONIC scaffold’s continuous air channels and hydrophobic interior, and reports high islet viability in a 6.6 mm-thick device. The Results sections report better survival than scaffold-free controls after transplantation into diabetic mice and confirm viable islets in the retrieved 6.6 mm device. (LLM, conf=0.93)

  cites [100] Wang LH, Ernst AU, An D, Datta AK, Epel B, Kotecha M, and Ma M (2021). A bioinspired scaffold for rapid oxygenation of cell encapsulation systems. Nat. Commun 12, 1– 16. 34615868 PMC8494927 source

In the paper

“This formulation was subsequently shown to prevent fibrosis and facilitate cell survival of allogeneic islets in non-human primates.”

What the sources say

• Partly supported

  The Methods section identifies Z1-Y15 as a triazole–thiomorpholine dioxide modification. The paper reports viable allogeneic islets in non-human primates and no pericapsular fibrotic overgrowth in six of seven animals after transplantation. That supports reduced fibrosis and islet survival, but not the unqualified claim that the formulation prevented fibrosis. (LLM, conf=0.86)

  cites [105] Bochenek MA, Veiseh O, Vegas AJ, McGarrigle JJ, Qi M, Marchese E, Omami M, Doloff JC, Mendoza-Elias J, Nourmohammadzadeh M, (2018). Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques. Nat. Biomed. Eng 2, 810– 821. 30873298 PMC6413527 sourceExperimental — accuracy not yet measured

In the paper

“These accessory mesenchymal stromal cells reduced infiltration of CD4+ and CD8+ effector T-cells and increased the number of Tregs to induce local immune tolerance.”

What the sources say

• Supported

  The Results section reports significantly lower CD4+ and CD8+ T-cell densities in grafts cotransplanted with engineered MSCs and more CD4+ Treg cells within those grafts. It describes the resulting graft environment as locally immune tolerant, while hedging its role in prolonged islet survival. (LLM, conf=0.91)

  cites [116] Wang X, Wang K, Yu M, Velluto D, Hong X, Wang B, Chiu A, Melero-Martin JM, Tomei AA, and Ma M (2022). Engineered immunomodulatory accessory cells improve experimental allogeneic islet transplantation without immunosuppression. Sci. Adv 8, 1– 17. PMC9307254 35867788 source

In the paper

“The incorporation of the CSF1R inhibitor GW2580 in its crystallized form within alginate microcapsules allowed for its controlled release overtime, resulting in long-term reduction of fibrosis and significant improvements in islet transplantation outcomes in mice, even within the subcutaneous space.”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [110] Farah S, Doloff JC, Müller P, Sadraei A, Han HJ, Olafson K, Vyas K, Tam HH, Hollister-Lock J, Kowalski PS, (2019). Long-term implant fibrosis prevention in rodents and non-human primates using crystallized drug formulations. Nat. Mater 18, 892– 904. 31235902 PMC7184801 source

In the paper

“Inflammatory cytokines, hypoxia, and hyperglycemia can all induce an ER stress response in β cells that leads to cell dysfunction and apoptosis.”

What the sources say

• Partly supported

  The “Causes of ER-stressed β cells” section says that inflammatory cytokines, hypoxia, and high glucose can each induce ER stress. It links chronic high glucose to β-cell dysfunction and death, but says ER stress–mediated death from cytokines is controversial and describes the link between hypoxia-mediated ER stress and apoptosis as a possibility, not an established outcome for all exposed cells. (LLM, conf=0.82)

  cites [127] Fonseca SG, Gromada J, and Urano F (2011). Endoplasmic reticulum stress and pancreatic β-cell death. Trends Endocrinol. Metab 22, 266– 274. 21458293 PMC3130122 sourceExperimental — accuracy not yet measured
• Partly supported

  The Introduction says inflammation can elicit severe ER stress in β-cells and that chronic, unresolved stress can produce a maladaptive response. The Discussion also identifies cytokines as a possible source of ER stress, but says the study did not mimic hyperglycemia or cytokine action; our copy does not identify hypoxia as a trigger or show that each named trigger leads to both dysfunction and apoptosis. (LLM, conf=0.88)

  cites [128] Chen CW, Guan BJ, Alzahrani MR, Gao Z, Gao L, Bracey S, Wu J, Mbow CA, Jobava R, Haataja L, (2022). Adaptation to chronic ER stress enforces pancreatic β-cell plasticity. Nat. Commun 13, 1– 18. 35941159 PMC9360004 sourceExperimental — accuracy not yet measured
• Partly supported

  The Abstract and Discussion report that proinflammatory cytokines are associated with ER-stress responses in β cells and that ER stress may contribute to impaired insulin secretion. They do not establish hypoxia or hyperglycemia as ER-stress triggers, or show that the resulting ER stress leads to apoptosis. (LLM, conf=0.86)

  cites [129] Tersey SA, Nishiki Y, Templin AT, Cabrera SM, Stull ND, Colvin SC, Evans-Molina C, Rickus JL, Maier B, and Mirmira RG (2012). Islet β-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model. Diabetes 61, 818– 827. 22442300 PMC3314371 sourceExperimental — accuracy not yet measured

In the paper

“These cells reversed diabetes and survived for at least 8 weeks in an autoimmune diabetes mouse model.”

What the sources say

• Supported

  The Results section reports that 2B10 SC-β cells reversed diabetes throughout the eight-week experiment in autoimmune diabetic NOD mice, without xeno-rejection. The same section identifies 2B10 as engineered to secrete IL-2 mutein, IL-10, and TGF-β. (LLM, conf=0.94)

  cites [54] Gerace D, Zhou Q, Kenty JH, Boulanger KR, Li H, Melton DA, Gerace D, Zhou Q, Kenty JH, Veres A, (2023). Engineering human stem cell-derived islets to evade immune rejection and promote localized immune tolerance. Cell Reports Med. 4, 100879. PMC9873825 36599351 source

In the paper

“Perturbations in normal metabolism and environmental conditions can induce endoplasmic reticulum (ER) stress and initiate the unfolded protein response (UPR).”

What the sources say

• Supported

  The “Protein homeostasis in the β cell” section says that glucose fluctuations and metabolic dysregulation can disrupt ER homeostasis and cause ER stress. It also explains that ER stress activates sensors that initiate the unfolded protein response; “Causes of ER-stressed β cells” gives fatty-acid exposure as another example. The paper discusses these conditions primarily in pancreatic β cells. (LLM, conf=0.88)

  cites [127] Fonseca SG, Gromada J, and Urano F (2011). Endoplasmic reticulum stress and pancreatic β-cell death. Trends Endocrinol. Metab 22, 266– 274. 21458293 PMC3130122 source

In the paper

“These hPSCs could differentiate into SC-islets that demonstrated protection from T-cell mediated rejection and reduced NK immune responses in allogeneic humanized mice.”

What the sources say

• Partly supported

  The Introduction and Discussion state that the edited hPSCs differentiated into insulin-producing β-like cells and were protected from T-cell-mediated rejection in a humanized mouse model. The Results report retained HLA-E expression and reduced NK-cell activation, but that response was measured in an in vitro assay, not in the mice; the reduction was observed for a subset of NK cells after IFNγ treatment. (LLM, conf=0.88)

  cites [55] Parent AV, Faleo G, Chavez J, Saxton M, Berrios DI, Kerper NR, Tang Q, and Hebrok M (2021). Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection. Cell Rep. 36, 109538. 34407395 PMC12416289 sourceExperimental — accuracy not yet measured

In the paper

“Allografts were able to survive indefinitely if also treated for the first 15 days with rapamycin, whereas those without FasL were rejected within 30 days.”

What the sources say

• Supported

  The Results section reports that all 45 SA-FasL-engineered mouse islet allografts survived indefinitely with daily rapamycin for 15 doses starting on transplantation day. All control islet grafts engineered with proteins other than FasL were rejected within 30 days. No page number is provided in the supplied passages. (LLM, conf=0.94)

  cites [114] Yolcu ES, Zhao H, Bandura-Morgan L, Lacelle C, Woodward KB, Askenasy N, and Shirwan H (2011). Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice. J. Immunol 187, 5901– 5909. 22068235 PMC3232043 source
• Supported

  The Results section, “Systemic donor-reactive responses persist despite long-term islet graft acceptance” (page unavailable), reports sustained survival of SA-FasL-engineered mouse islet allografts after 15 daily rapamycin doses, with a 100-day observation period. Control grafts without FasL, given the same regimen, were acutely rejected with a mean survival time of 24 ± 2.3 days. The Abstract describes the engineered grafts as surviving indefinitely. (LLM, conf=0.90)

  cites [115] Woodward KB, Zhao H, Shrestha P, Batra L, Tan M, Grimany-Nuno O, Bandura-Morgan L, Askenasy N, Shirwan H, and Yolcu ES (2020). Pancreatic islets engineered with a FasL protein induce systemic tolerance at the induction phase that evolves into long-term graft-localized immune privilege. Am. J. Transplant 20, 1285– 1295. 31850658 PMC7299172 source

In the paper

“The HLA class I molecules A, B, and C are present on all nucleated cells and present antigens to CD8+ cytotoxic T-cells, while HLA class II proteins activate CD4+ helper T-cells.”

What the sources say

• ?Could not verify

  No passage from our copy matched the claim. Searches for HLA, MHC class I, CD8 T cells, and CD4 T cells returned no passages, so the copy does not establish the stated distribution or functions of HLA class I and II molecules. (LLM, conf=0.72)

  cites [117] Bluestone JA, and Tang Q (2020). Solving the Puzzle of Immune Tolerance for β-Cell Replacement Therapy for Type 1 Diabetes. Cell Stem Cell 27, 505– 507. 33007232 sourceExperimental — accuracy not yet measured

In the paper

“For example, alginate microcapsules fabricated to release the immunomodulatory chemokine CXCL12 improved encapsulated SC-islet survival and reduced the fibrotic response in mice.”

What the sources say

• Supported

  The Introduction (section 1) says CXCL12 was incorporated into alginate microcapsules and that co-encapsulated SCβ cells evaded the pericapsular fibrotic response while retaining long-term function in mice. The paper also describes the capsules as CXCL12-releasing and reports prolonged cell viability (section 3.5). (LLM, conf=0.94)

  cites [108] Alagpulinsa DA, Cao JJL, Driscoll RK, Sirbulescu RF, Penson MFE, Sremac M, Engquist EN, Brauns TA, Markmann JF, Melton DA, (2019). Alginate-microencapsulation of human stem cell–derived β cells with CXCL12 prolongs their survival and function in immunocompetent mice without systemic immunosuppression. Am. J. Transplant 19, 1930– 1940. 30748094 source

In the paper

“They demonstrated that FasL induced local immune tolerance by causing apoptosis in alloreactive T-cells and as well as promoting the development of regulatory T-cells (Tregs) for long-term maintenance.”

What the sources say

• Supported

  The Discussion reports more apoptotic effector T cells in SA-FasL islet grafts and describes elimination of alloreactive T cells as a mechanism of localized tolerance. The Results section, “Localized tolerance is induced and maintained by Treg cells” (page not supplied), reports that depleting Tregs even after tolerance was established prompted graft rejection. The paper presents this finding in mice receiving SA-FasL-engineered islets. (LLM, conf=0.91)

  cites [114] Yolcu ES, Zhao H, Bandura-Morgan L, Lacelle C, Woodward KB, Askenasy N, and Shirwan H (2011). Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice. J. Immunol 187, 5901– 5909. 22068235 PMC3232043 source
• Partly supported

  The Results report that SA-FasL-engineered islets induced death of alloreactive T cells, and the Discussion says Treg cells are required to maintain long-term graft-localized immune privilege. However, the Discussion presents generation of Tregs in the graft milieu as a possibility, not a demonstrated effect of FasL; it also distinguishes systemic tolerance during induction from local immune privilege during maintenance. No page numbers are available in our copy. (LLM, conf=0.84)

  cites [115] Woodward KB, Zhao H, Shrestha P, Batra L, Tan M, Grimany-Nuno O, Bandura-Morgan L, Askenasy N, Shirwan H, and Yolcu ES (2020). Pancreatic islets engineered with a FasL protein induce systemic tolerance at the induction phase that evolves into long-term graft-localized immune privilege. Am. J. Transplant 20, 1285– 1295. 31850658 PMC7299172 sourceExperimental — accuracy not yet measured

In the paper

“Fortunately, while they may be detrimental to SC-β cell potency,47 no safety issues have been reported to date.”

What the sources say

• Supported

  In “Purification of endocrine and SC-β cells” (page not available), the paper reports that purified clusters contained fewer than 5% SC-EC cells and had higher glucose-stimulated insulin-secretion indices than unsorted clusters. This supports the hedged suggestion that SC-EC cells may reduce potency, though it does not establish a causal effect. Citation 47 follows the potency clause; the separate statement about safety is not attributed to this source. (LLM, conf=0.84)

  cites [47] Veres A, Faust AL, Bushnell HL, Engquist EN, Kenty JH, Harb G, Quinn P, Poh Y, Sintov E, Gürtler M, Charting cellular identity during human in vitro β - cell differentiation. Nature, 368– 373. PMC6903417 31068696 source

In the paper

“To specifically improve oxygen levels at the transplantation site, oxygen generating materials have been inserted alongside the islet graft,96,98,99 while another strategy directly pumps oxygen into an encapsulation device92,97.”

What the sources say

• Partly supported

  The study reports that oxygen-generating PDMS–calcium peroxide disks improved oxygenation and survival in cultured rat islets and 3D constructs (study summary; Coculture methods). It describes use during transplantation as a prospective application, not a demonstrated improvement at a transplantation site (Discussion). The separate claim about pumping oxygen into a device is attached to other citations, not this paper. (LLM, conf=0.86)

  cites [96] Pedraza E, Coronel MM, Fraker CA, Ricordi C, and Stabler CL (2012). Preventing hypoxia-induced cell death in beta cells and islets via hydrolytically activated, oxygen-generating biomaterials. Proc. Natl. Acad. Sci 109, 4245– 4250. 22371586 PMC3306668 sourceExperimental — accuracy not yet measured
• Supported

  The Results section, “Design and Fabrication of Macroencapsulation Devices,” says an oxygen-generating OxySite disk was placed in the center of a device containing encapsulated cells. The paper reports improved islet survival with OxySite. The separate claim about pumping oxygen is attached to other citations, not this source. (LLM, conf=0.92)

  cites [98] Coronel MM, Liang JP, Li Y, and Stabler CL (2019). Oxygen generating biomaterial improves the function and efficacy of beta cells within a macroencapsulation device. Biomaterials 210, 1– 11. 31029812 PMC6527135 source
• Supported

  The citation is attached to the second strategy, not the claim about materials placed alongside an islet graft. The Introduction describes directly injecting O₂ into an encapsulation device, and the Discussion describes daily injections into the βAir device’s gas-permeable chamber. These support the citing sentence’s description of directly supplying oxygen to a device. (LLM, conf=0.90)

  cites [99] Wang L-H, Ernst AU, Flanders JA, Liu W, Wang X, Datta AK, Epel B, Kotecha M, Papas KK, and Ma M (2021). An inverse-breathing encapsulation system for cell delivery. Sci. Adv 7, 5835– 5849. PMC8121434 33990318 source

In the paper

“Furthermore, while SC-islets appear to be generally more stress-resistant than isolated primary islets,136 they nevertheless respond to inflammatory cytokines with similar stress response pathways,137”

What the sources say

• Supported

  The Results section reports that both SC-islets and human islets increased expression of β-cell-stress and immune-interaction genes after stress treatment, with the strongest increases when cytokines were included. The Discussion describes a similar stress-related gene-expression pattern in the two islet types. This supports the cytokine-response clause attributed to this source; the preceding stress-resistance clause carries a different citation. (LLM, conf=0.91)

  cites [136] Leite NC, Pelayo GC, and Melton DA (2022). Genetic manipulation of stress pathways can protect stem-cell-derived islets from apoptosis in vitro. Stem Cell Reports 17, 766– 774. 35245439 PMC9023776 source
• Supported

  Citation 137 is attached to the cytokine-response clause, not the preceding stress-resistance comparison, which cites 136. The Discussion states that iPSC-derived beta cells activate signaling pathways and downstream stress responses similar to those in human islets after cytokine exposure. (LLM, conf=0.94)

  cites [137] Demine S, Schiavo AA, Marín-Cañas S, Marchetti P, Cnop M, and Eizirik DL (2020). Pro-inflammatory cytokines induce cell death, inflammatory responses, and endoplasmic reticulum stress in human iPSC-derived beta cells. Stem Cell Res. Ther 11, 1– 15. 31900242 PMC6942385 source

In the paper

“For SC-islet transplantations, site and dose have been shown to influence cure efficacy in mice, with placement underneath the highly-vascularized kidney capsule producing much better results than subcutaneous infusions.143,150”

What the sources say

• Partly supported

  The Results section, “Attrition of SCIPC and Mature Islet Grafts after Transplant” (page unavailable), reports better SCIPC graft survival under the highly vascularized kidney capsule than at a subcutaneous site. But it measured graft survival in non-diabetic mice, not cure efficacy, and does not establish an effect of transplant dose on cure. (LLM, conf=0.88)

  cites [143] Faleo G, Russ HA, Wisel S, Parent AV, Nguyen V, Nair GG, Freise JE, Villanueva KE, Szot GL, Hebrok M, (2017). Mitigating Ischemic Injury of Stem Cell-Derived Insulin-Producing Cells after Transplant. Stem Cell Reports 9, 807– 819. 28803916 PMC5599226 sourceExperimental — accuracy not yet measured
• Supported

  The Conclusion reports that 2 million SC-islet cells reversed diabetes in mice whereas 0.75 million did not, and that kidney-capsule transplantation produced better glycemic control than subcutaneous transplantation. The Discussion describes rapid vascularization at the kidney-capsule site. (LLM, conf=0.93)

  cites [150] Maxwell KG, Kim MH, Gale SE, and Millman JR (2022). Differential function and maturation of human stem cell-derived islets after transplantation. Stem Cells Transl. Med 11, 322– 331. 35294547 PMC8968674 source

In the paper

“Large scale (>1,000 L) bioreactors for mammalian cell culture have been used in the biotechnology industry for decades.177”

What the sources say

• Supported

  The Introduction reports an 8,000 L animal-cell bioreactor by the mid-1980s and 2,000 L systems in the 1980s. It also describes commercial 20,000 L bioreactors by 2006, supporting the claim that bioreactors above 1,000 L had been used for decades. (LLM, conf=0.90)

  cites [177] Nienow AW (2006). Reactor engineering in large scale animal cell culture. Cytotechnology 50, 9– 33. 19003068 PMC3476006 source

In the paper

“Furthermore, these gene knockdowns decreased T-cell activation and T-cell induced apoptosis when SC-islets were co-cultured with peripheral blood mononuclear cells.”

What the sources say

• Partly supported

  The Results section ('Genetic manipulation increases protection of SC-islets from apoptosis mediated by allorecognition in vitro'; page not provided) reports reduced T-cell activation and fewer apoptotic SC-islets after gene knockdown and co-culture with allogeneic T1D PBMCs. It attributes the apoptosis to stress and allorecognition, but does not establish that T cells specifically induced it. (LLM, conf=0.82)

  cites [136] Leite NC, Pelayo GC, and Melton DA (2022). Genetic manipulation of stress pathways can protect stem-cell-derived islets from apoptosis in vitro. Stem Cell Reports 17, 766– 774. 35245439 PMC9023776 sourceExperimental — accuracy not yet measured

In the paper

“For example, implanting a device into the subcutaneous space one month prior to cell transplantation pre-vascularized the graft site and avoided the several week lag time that it takes for vascularization to occur.145,151”

What the sources say

• ?Not checked — no full text of the sourcecites [145] Pepper AR, Gala-Lopez B, Pawlick R, Merani S, Kin T, and Shapiro AMJ (2015). A prevascularized subcutaneous device-less site for islet and cellular transplantation. Nat. Biotechnol 33, 518– 523. 25893782 source
• Partly supported

  The Introduction describes temporarily implanting an angiocatheter to create a vascularized subcutaneous site before infusing the cell graft, and Experimental Procedures confirms that vascular catheters were used to prepare the site. Our copy does not specify implantation one month before transplantation or state that this avoided a several-week vascularization lag. (LLM, conf=0.84)

  cites [151] Pepper AR, Pawlick R, Bruni A, Wink J, Rafiei Y, O’Gorman D, Yan-Do R, Gala-Lopez B, Kin T, MacDonald PE, (2017). Transplantation of human pancreatic endoderm cells reverses diabetes post transplantation in a prevascularized subcutaneous site. Stem Cell Reports 8, 1689– 1700. 28591651 PMC5470173 sourceExperimental — accuracy not yet measured

In the paper

“Stress from a high glucose environment can cause downregulation of key islet genes and decreased function in human islets135 and animal models123, implicating that adequate glucose control is important for β cell health in the immediate aftermath of transplantation.”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [135] Dai C, Kayton NS, Shostak A, Poffenberger G, Cyphert HA, Aramandla R, Thompson C, Papagiannis IG, Emfinger C, Shiota M, (2016). Stress-impaired transcription factor expression and insulin secretion in transplanted human islets. J. Clin. Invest 126, 1857– 1870. 27064285 PMC4855919 source
• Partly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [123] Biarnés M, Montolio M, Nacher V, Raurell M, Soler J, and Montanya E (2002). β-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 51, 66– 72. 11756324 sourceExperimental — accuracy not yet measured

In the paper

“Incorporating vascular endothelial growth factor (VEGF)-releasing capsules into a similar pre-vascularization strategy152 or transplanting islets within VEGF-releasing hydrogels153 were shown to further improve vessel formation.”

What the sources say

• Supported

  The Conclusions report that VEGF-coated capsules produced deeper microvascular infiltration than native scaffolds, yielding a pre-vascularized pouch in rats. Citation 152 attaches to the capsule strategy, not the separate claim about VEGF-releasing hydrogels. (LLM, conf=0.92)

  cites [152] Kasoju N, Pátíková A, Wawrzynska E, Vojtíţková A, Sedlačík T, Kumorek M, Pop-Georgievski O, Sticová E, Kříž J, and Kubies D (2020). Bioengineering a pre-vascularized pouch for subsequent islet transplantation using VEGF-loaded polylactide capsules. Biomater. Sci 8, 631– 647. 31729495 source
• Supported

  The Results section reports that islets transplanted in PEG-VEGF hydrogels had a higher density of vascularized islets, especially at the EFP site. The cited paper supports the hydrogel-and-islet portion attached to citation 153; the separate capsule strategy is attached to citation 152. (LLM, conf=0.92)

  cites [153] Weaver JD, Headen DM, Aquart J, Johnson CT, Shea LD, Shirwan H, and García AJ (2017). Vasculogenic hydrogel enhances islet survival, engraftment, and function in leading extrahepatic sites. Sci. Adv 3. PMC5457148 28630926 source

In the paper

“Specifically, SC-islets exhibited dysfunction, apoptosis, and increased expression of genes related to stress and immune interaction when exposed to a variety of stressors, including a cytokine mix to mimic inflammatory stress, thapsigargin to induce ER stress, and high glucose to replicate metabolic stress.”

What the sources say

• Supported

  The Results section, “SC-islets and human islets are vulnerable to stress in vitro,” identifies the cytokine mix, thapsigargin, and high glucose as inflammatory, ER, and metabolic stressors, respectively. It reports increased apoptosis, impaired glucose-stimulated insulin secretion, and increased expression of β-cell stress and immune-interaction genes in stressed SC-islets. The Discussion reiterates these findings. (LLM, conf=0.95)

  cites [136] Leite NC, Pelayo GC, and Melton DA (2022). Genetic manipulation of stress pathways can protect stem-cell-derived islets from apoptosis in vitro. Stem Cell Reports 17, 766– 774. 35245439 PMC9023776 source

In the paper

“Lentiviral shRNA knockdown of XBP1, CDKN1A, NLRC5, and β2M decreased the level of apoptosis in SC-islets when treated with these stressors as well as downregulated the expression of genes associated with stress responses and immune interaction.”

What the sources say

• Supported

  The Results section, under “Genetic manipulation is associated with protection of SC-islets from stress-mediated apoptosis and dysfunction,” describes lentiviral shRNA targeting of XBP1, CDKN1A, NLRC5, and β2M. It reports less apoptosis after stressor treatment and decreased expression of β-cell-stress and immune-interaction genes relative to the non-target control. (LLM, conf=0.94)

  cites [136] Leite NC, Pelayo GC, and Melton DA (2022). Genetic manipulation of stress pathways can protect stem-cell-derived islets from apoptosis in vitro. Stem Cell Reports 17, 766– 774. 35245439 PMC9023776 source

In the paper

“Critically, PSCs are sensitive to mechanical cues,179,180 and changes in shear stress due to increases in reactor volume as well as impeller speed and size will require careful optimization.”

What the sources say

• ?Not checked — no full text of the sourcecites [179] Niebruegge S, Bauwens CL, Peerani R, Thavandiran N, Masse S, Sevaptisidis E, Nanthakumar K, Woodhouse K, Husain M, Kumacheva E, (2009). Generation of human embryonic stem cell-derived mesoderm and cardiac cells using size-specified aggregates in an oxygen-controlled bioreactor. Biotechnol. Bioeng 102, 493– 507. 18767184 source
• Supported

  The citation follows the statement that PSCs are sensitive to mechanical cues. The Abstract and Conclusions report that mouse iPS cells grown on microcarriers had a narrow range of spin rates supporting growth and were sensitive to shear forces. The later statement about reactor volume and impeller size is not attached to this citation. (LLM, conf=0.91)

  cites [180] Ismadi MZ, Gupta P, Fouras A, Verma P, Jadhav S, Bellare J, and Hourigan K (2014). Flow characterization of a spinner flask for induced pluripotent stem cell culture application. PLoS One 9. PMC4184809 25279733 source

In the paper

“The endocrine cells are then single-cell dispersed from the culture surface and aggregated into islet-like clusters in suspension culture.”

What the sources say

• Supported

  The Online Methods (SC-β Cell Differentiation, Planar Protocol; page not specified) state that, after seven days on the plate, cells could be single-cell dispersed with TrypLE and moved to suspension on an orbital shaker. The Results (A planar SC-β cell differentiation method; page not specified) confirm that the cells were aggregated into clusters after one week in stage 6. (LLM, conf=0.94)

  cites [39] Hogrebe NJ, Augsornworawat P, Maxwell KG, Velazco-Cruz L, and Millman JR (2020). Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells. Nat. Biotechnol 38, 460– 470. 32094658 PMC7274216 source
• Supported

  The Experimental design section describes single-cell dispersion from the plate followed by aggregation into islet-like clusters using an orbital shaker. It specifies that this is an optional step after endocrine-cell specification, rather than a required part of the planar differentiation protocol. (LLM, conf=0.90)

  cites [57] Hogrebe NJ, Maxwell KG, Augsornworawat P, and Millman JR (2021). Generation of insulin-producing pancreatic β cells from multiple human stem cell lines. Nat. Protoc 16, 4109– 4143. 34349281 PMC8529911 source

In the paper

“Furthermore, a stem cell-derived product could also be genetically engineered to have advantageous features not found in primary islets, such as resistance to stressors like hypoxia or being able to evade the host immune system.”

In the paper

“Furthermore, these cells were transplanted without an immune-protective device to avoid problems with nutrient exchange and fibrosis, and thus the patients required immunosuppressive drugs to ensure graft survival.”

In the paper

“Rather, as long as the β cells secrete insulin properly in response to glucose stimulation and are transplanted in a location that facilitates adequate exchange of these molecules with the blood stream, such a cell replacement therapy could provide a functional cure for T1D.”

In the paper

“These stem cell-derived islets (SC-islets) could be generated from a single cell source using a standardized process, and the resulting cell product could be well-characterized to allow for more predictable transplant outcomes.”

In the paper

“While the primates did not achieve complete insulin independence, the transplanted SC-islets significantly reduced their insulin requirements and greatly improved their glycemic control, further illustrating their potential utility as a therapy.”

What the sources say

• ?Not checked — no full text of the sourcecites [45] Du Y, Liang Z, Wang S, Sun D, Wang X, Liew SY, Lu S, Wu S, Jiang Y, Wang Y, (2022). Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates. Nat. Med 28, 272– 282. 35115708 source
• ?Not checked — no full text of the sourcecites [46] Luo Z, Zhan J, Wu S, Jiang Y, Lu Z, Wang Z, Yi LS, Zhang Y, Sun W, Fang X, (2023). Implantation underneath the abdominal anterior rectus sheath enables effective and functional engraftment of stem-cell-derived islets. Nat. Metab 5, 29– 40. 36624157 source

In the paper

“The first two patients were given half the anticipated target dose to assess the safety profile of their stem-cell derived product, VX-880.”

In the paper

“Importantly, these remarkable studies demonstrated that the concept of replacing β cell mass by transplanting pancreatic islets was relatively safe and effective in treating T1D.”

In the paper

“While the initial findings have not yet been peer-reviewed, positive preliminary results reported in a press release have indicated that transplantation of these SC-islets improved glycemic control in these two T1D patients (https://www.businesswire.com/news/home/20220606005424/en/).”

What the sources say

• ?Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  cites https://www.businesswire.com/news/home/20220606005424/en/

In the paper

“The developmental pathways targeted by this process can be very sensitive to changes in timing and signaling intensity, and thus small signaling changes at specific times can lead to large changes in cell fate selection.”

In the paper

“For the typical T1D patient that is able to achieve their blood sugar targets with insulin injections as indicated by their hemoglobin A1c levels, the potentially severe adverse side effects of life-long immunosuppression may not outweigh the benefits of further improved glycemic control.”

In the paper

“Consequently, many attempts to improve SC-islet generation consist of iterations with different combinations and timings of soluble factors.”

In the paper

“A substantial fraction can be α cells along with some δ cells.”

In the paper

“The latest generation of protocols are better at generating islet-like clusters consisting of mostly endocrine cells, though not all of these are β cells.”

In the paper

“For example, conceptually, if insulin secretion per cell is doubled, then potentially only half as many cells are needed to cure a patient.”

In the paper

“However, further enhancing SC-islets to better mimic the functionality of primary adult islets would reduce the number of cells required for transplantation and make it easier to manufacture sufficient cell numbers.”

In the paper

“Moreover, the chromatin accessibilities of primary adult islet cell types were much more restricted than those in SC-islet cell types, where the INS gene remained open in SC-α and SC-δ cells in addition to SC-β cells.”

What the sources say

• Not checked yetcites [75] Augswornworawat P, Hogrebe NJ, Ishahak M, Marquez E, Maestas M, Schmidt M, Veronese-Paniagua D, Gale S, Miller J, Velazco-Cruz L, (2022). Defining the chromatin and transcriptional landscape of stem cell-derived islets. BioRxiv, 1– 59.

In the paper

“Specifically, there appeared to be SC-β cell subpopulations that expressed TPH1, a known marker of SC-EC cells, and that had increased accessibility of binding sites for LMX1A, a transcription factor associated with the SC-EC cell fate.”

What the sources say

• Not checked yetcites [75] Augswornworawat P, Hogrebe NJ, Ishahak M, Marquez E, Maestas M, Schmidt M, Veronese-Paniagua D, Gale S, Miller J, Velazco-Cruz L, (2022). Defining the chromatin and transcriptional landscape of stem cell-derived islets. BioRxiv, 1– 59.

In the paper

“Reducing graft volume facilitates an easier transplantation procedure, reduces nutrient exchange requirements at the transplantation site, and opens alternative transplantation site possibilities.”

In the paper

“Reducing the required cell number is significant in terms of both the graft volume that needs to be transplanted as well as cell production costs.”

In the paper

“Consequently, increasing insulin secretion per cell in SC-islets can be achieved through improvements in either SC-β cell maturation or by decreasing the percentage of these off-target cell populations.”

In the paper

“First, SC-β cells generated with current directed differentiation protocols are still not quite as functional as primary human islets, and their transcriptional and chromatin landscape remains immature.”

In the paper

“Avoiding the use of biomaterials altogether eliminates the inherent diffusion barriers of encapsulation systems as well as circumvents the biomaterial-induced fibrotic response.”

In the paper

“By only targeting the area directly surrounding the implant, these strategies can increase the efficacy of the desired immune modulation while simultaneously avoiding systemic side-effects.”

In the paper

“They then combined this zwitterionic concept with the previously discovered triazole modification to further improve the ability of the alginate microcapsules to resist fibrosis and as well as enhance their mechanical stability.”

What the sources say

• ?Not checked — no full text of the sourcecites [107] Liu Q, Chiu A, Wang L, An D, Li W, Chen EY, Zhang Y, Pardo Y, McDonough SP, Liu L, (2020). Developing mechanically robust, triazole-zwitterionic hydrogels to mitigate foreign body response (FBR) for islet encapsulation. Biomaterials 230, 119640. 31791840 source

In the paper

“These findings suggested that extended time in vivo tended to open chromatin regions associated with cell-specific identity and maturation, while in vitro culture methods remained relatively ineffective at promoting the same maturation effect.”

What the sources say

• Not checked yetcites [75] Augswornworawat P, Hogrebe NJ, Ishahak M, Marquez E, Maestas M, Schmidt M, Veronese-Paniagua D, Gale S, Miller J, Velazco-Cruz L, (2022). Defining the chromatin and transcriptional landscape of stem cell-derived islets. BioRxiv, 1– 59.

In the paper

“Advances in islet isolation methodologies, immunotherapies, and transplantation techniques have improved islet transplantation outcomes in recent years, improving 5-year insulin independence rates to 50-80%.”

What the sources say

• ?Not checked — no full text of the sourcecites [23] Verhoeff K, Marfil-Garza BA, and Shapiro AMJ (2021). Update on islet cell transplantation. Curr. Opin. Organ Transplant 26, 397– 404. 34148980 source

In the paper

“Discovering new ways to further address the acute stressors experienced by islets in the immediate aftermath of transplantation could further reduce the degree of β cell loss and dysfunction that impedes long-term restoration of normoglycemia.”

What the sources say

• ?Not checked — no full text of the sourcecites [126] Emamaullee JA, and Shapiro AMJ (2007). Factors influencing the loss of β-cell mass in islet transplantation. Cell Transplant. 16, 1– 8. 28880676 source

In the paper

“Alternatively, increasing the surface-to-volume ratio and decreasing the distance of cells from the outer surface of the device can facilitate better mass transport to the encapsulated cells.”

In the paper

“These sites require a less invasive procedure for transplantation and provide easier access to the graft so that it can be monitored and possibly removed if problems arise.”

In the paper

“Furthermore, this location promoted robust vascularization by week 12 and promoted an environment that allowed for SC-islet maturation.”

What the sources say

• ?Not checked — no full text of the sourcecites [46] Luo Z, Zhan J, Wu S, Jiang Y, Lu Z, Wang Z, Yi LS, Zhang Y, Sun W, Fang X, (2023). Implantation underneath the abdominal anterior rectus sheath enables effective and functional engraftment of stem-cell-derived islets. Nat. Metab 5, 29– 40. 36624157 source

In the paper

“Loss of function of the p53 protein is common in the majority of cancers,164”

What the sources say

• ?Not checked — no full text of the sourcecites [164] Muller PAJ, and Vousden KH (2013). P53 mutations in cancer. Nat. Cell Biol 15, 2– 8. 23263379 source

In the paper

“These cells are able to rapidly cure severely diabetic mice and improve glycemic control in non-human primates, and continued progress has allowed the field to narrow in on the critical quality attributes of these cells (Figure 3).”

In the paper

“While this protocol is able to robustly generate functional SC-islets in a lab setting, this air-liquid interface culture system would be difficult to adapt to large-scale manufacturing.”

What the sources say

• ?Not checked — no full text of the sourcecites [37] Rezania A, Bruin JE, Arora P, Rubin A, Batushansky I, Asadi A, O’Dwyer S, Quiskamp N, Mojibian M, Albrecht T, (2014). Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol 32, 1121– 1133. 25211370 source

In the paper

“These data on the transcriptional and chromatin landscape of SC-islet cell types can guide the next generation of protocols for refining SC-islet production in an effort to increase insulin secretion per cell and eliminate off-target cell types.”

In the paper

“Finally, further genetic engineering approaches to improve SC-islet resistance to the stressors they experience immediately after transplantation will likely be key to improving graft viability and reducing the number of cells needed for insulin independence.”

In the paper

“For example, single-cell sequencing technologies have allowed for unprecedented characterization of SC-islets, providing insight into the identity and maturation state of the cells produced with these differentiation protocols.”

In the paper

“These approaches offer the potential for avoiding immunosuppressive drugs altogether, broadening the applicability of this cell therapy.”

In the paper

“Furthermore, this population could be well-characterized and facilitate the generation of a master cell bank of high-quality pancreatic progenitors.”

In the paper

“and it could potentially be scaled up further using cell stacks or hyperflask setups.”